Related Experiment Video

Updated: Sep 27, 2026

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
10:26

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Published on: December 20, 2017

Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological

Jung-Sik Kim1, Heather Crooks, Aaron Foxworth

  • 1Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, USA.

Molecular Cancer Therapeutics
|January 9, 2003
PubMed

Insights

Activated beta-catenin drives colon cancer progression. Pharmacological inhibition may treat some cancers, but its necessity varies by cell line, showing potential therapeutic applications in a subset of colon cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Beta-catenin activation is crucial in human cancer pathogenesis, particularly colon adenocarcinoma.
  • Targeting activated beta-catenin is a potential anticancer strategy due to its gain-of-function properties.

Purpose of the Study:

  • To determine if activated beta-catenin is essential for maintaining tumorigenic properties in advanced human colon cancer cells.
  • To provide proof-of-principle for targeting activated beta-catenin as an anticancer therapeutic.

Main Methods:

  • Utilized a novel clonal growth assay.
  • Employed human somatic cell gene targeting.
  • Investigated beta-catenin's oncogenic role in SW48, DLD1, and HCT116 colon cancer cell lines.

Main Results:

  • Demonstrated that beta-catenin is a necessary oncogene in SW48 and DLD1 colon cancer cells.
  • Showed that beta-catenin is not a necessary oncogene in HCT116 colon cancer cells.
  • Indicated that activated beta-catenin remains a critical oncogenic stimulus throughout colon cancer progression in specific cell types.

Conclusions:

  • Activated beta-catenin can be a critical oncogenic stimulus in advanced human colon cancer.
  • Small molecule inhibitors targeting activated beta-catenin show promise as anticancer therapeutics for a subset of colon cancers.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...